e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Clinical problems in mediastinal and pleural malignacies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pleural eicosanoids in patients with lung cancer
J. H. Cho, S. Park, H. Nam, S. Kwak, J. Ryu, H. Lee (Incheon, Seoul, Republic Of Korea)
Source:
Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Session:
Clinical problems in mediastinal and pleural malignacies
Session type:
Poster Discussion
Number:
3077
Disease area:
Respiratory infections, Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. H. Cho, S. Park, H. Nam, S. Kwak, J. Ryu, H. Lee (Incheon, Seoul, Republic Of Korea). Pleural eicosanoids in patients with lung cancer. Eur Respir J 2013; 42: Suppl. 57, 3077
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Mucus production, lung inflammation and functional decay in IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions?
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Serum levels of sestrin 2 in patients with sarcoidosis
Source: International Congress 2014 – ILDs 6
Year: 2014
The role of CCR2
+
CD4
+
T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Role of Dr-70 immunoassay in suspected malignant pleural effusion
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014
Titel: MicroRNA analysis in Epithelial Lining Fluid (ELF) compared to Bronchoalveolar Lavage (BAL) in Interstitial pulmonary fibrosis (IPF)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013
Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014
Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion
Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies
Year: 2014
Serum procalcitonin is useful in differentiating between drug-induced pneumonitis and bacterial pneumonia
Source: International Congress 2014 – ILDs 5
Year: 2014
Biomarkers for interstitial lung disease
Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease
Year: 2016
Analysis of amylase rich pleural effusions
Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases
Year: 2013
Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014
Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion
Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions
Year: 2013
Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer
Source: International Congress 2016 – Orphan diseases I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept